Last reviewed · How we verify
NCT07132606
The Predictive Value of Serum Histone Succinylation in Malignant Solid Tumors
trial in Malignant Tumors in 1,000 participants. Not yet recruiting.
31 December 2025
Quick facts
| Lead sponsor | Yinghua Ji |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 20 August 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 1 August 2026 |
Conditions studied
- Malignant Tumors — all drugs for Malignant Tumors →
Sponsor
Yinghua Ji
Who can join
18 and older, any sex, with Malignant Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In recent years, advances in protein post-translational modification (PTM) research have revealed histone succinylation as a novel epigenetic modification mechanism critically involved in tumor initiation, progression, and prognosis. Succinylation alters protein physicochemical properties and functions, thereby modulating cellular metabolism, proliferation, and apoptosis. Aberrant histone succinylation in tumor cells demonstrates significant correlations with tumor type, staging, and clinical outcomes, offering new avenues for early cancer diagnosis. This project utilizes blood serum samples to quantify histone succinylation levels through modification-specific antibody-based detection. Integrated with clinical data, this approach enables early, rapid, and accurate pan-cancer diagnosis, achieving tumor screening via a single-tube blood test. It represents a paradigm shift in precision oncology from "gene-driven" to "epigenetic-metabolic-driven" early detection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07132606
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Malignant Tumors
Currently open trials in the same condition.
- NCT07112222 — A Study of LM-350 in Subjects With Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT07301801 — Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors · EARLY_PHASE1 · recruiting
- NCT07004244 — Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies · Phase 1 · recruiting
- NCT06944444 — A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors · Phase 1 · recruiting
- NCT05714748 — Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors · Phase 1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07132606 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yinghua Ji
- Last refreshed: 20 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07132606.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing